open
serve
block
verse
w
o
rdys
billionaire
.ai
your
list
Whiteboard
App
quizie
un
school
New Journal
News
Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Ask Genius
Apps
IJR News — today's news from every side
Ask Genius
Apps
Trending
Novartis MS pill beats Aubagio in two large phase 3 trials
x/novartis
— Sep 1, 2026
Novartis reported positive Phase 3 REMODEL-1 and REMODEL-2 results for the BTK inhibitor remibrutinib in relapsing multiple sclerosis, showing lower annualized relapse rate and meaningful reductions in disability progression versus teriflunomide and prompting worldwide regulatory filings. With remibrutinib already approved for chronic spontaneous urticaria as Rhapsido, the drug’s MS potential could become a major growth driver given its favorable safety profile and strong early sales signals.
+6
2
Share
Rachel Meyers
Teriflunomide isn't the toughest comparator out there, would like to see how remibrutinib stacks up against some of the stronger existing MS drugs before getting too excited.
